Enthera Pharmaceuticals is focused on developing first-in-class biologics aimed at treating severe autoimmune disorders, particularly inflammatory bowel disease (IBD) and type 1 diabetes (T1D). The company’s innovative therapeutic approach is centered on the IGFBP3/TMEM219 pathway, which is crucial in regulating cell apoptosis in various organs, including the gut and pancreas. By targeting this pathway, Enthera aims to preserve and restore organ cell function, thereby transforming the treatment landscape for these challenging conditions. Their lead candidate, Ent001, is a monoclonal antibody designed to inhibit TMEM219, preventing the apoptosis of colonic stem cells and insulin-producing beta cells, which are critical in the pathogenesis of IBD and T1D.

Currently, Ent001 is undergoing a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy volunteers, laying the groundwork for future studies in patients with IBD and T1D. The company has reported promising preclinical data indicating that Ent001 can promote mucosal healing in the gastrointestinal tract, suggesting its potential as a novel treatment option for inflammatory bowel diseases. Enthera's commitment to advancing its research is supported by a robust patent portfolio and backing from notable investors, positioning the company as a key player in the biotech sector focused on autoimmune therapies.

Italy

We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases

Enthera Pharmaceuticals

Company Details